A major pharmacological goal is targeting oncogenic transcription factors, by the assumption that lowering disease-promoting protein levels is generally beneficial. For example, inhibiting metastasis activator BACH1 is proposed to decrease metastasis in human cancers. Testing such assumptions requires measuring disease phenotypes while precisely adjusting disease-promoting protein levels, which is not routinely available. Here we develop a strategy to insert protein-level tuning synthetic gene circuits into the same genomic locus of human cell lines. Unexpectedly, the invasiveness of engineered MDA-MB-231 metastatic breast cell increases and then decreases while tuning BACH1 levels up. BACH1 expression-shifts in invading cells, and expression of BACH1’s direct target RKIP confirm BACH1’s nonmonotone phenotypic and regulatory effects. Thus, inhibiting BACH1 can be harmful and promoting BACH1, beneficial. Additionally, BACH1’s expression variability aids invasion at high BACH1 expression. Overall, precisely engineered protein level control is necessary and sufficient to unravel disease effects of genes, thereby improving the efficiency of drug development.